vTv Therapeutics Inc（VTVT）財務資料VTVTvTv Therapeutics Inc

Evaluating the bottom line, vTv Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -10.95%, provide a clear picture of how effectively VTVT converts its operational activities into shareholder value.

In the context of the broader market, VTVT competes directly with industry leaders such as VANI and NRXP. With a market capitalization of $83.63M, it holds a significant position in the sector. When comparing efficiency, VTVT's gross margin of N/A stands against VANI's N/A and NRXP's 32.70%. Such benchmarking helps identify whether vTv Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown volatility in earnings, with a significant EPS of 1.65 in Q1 2026 but a subsequent miss in Q2 with -1.05. The gross margin is strong at 100% for Q1 2026, but the net income has fluctuated widely, with a net income of 24.13 million in Q1 followed by losses in subsequent quarters.